Ameliorative effect of fluvoxamine against colon carcinogenesis via COX-2 blockade with oxidative and metabolic stress reduction at the cellular, molecular and metabolic levels
oleh: Pranesh Kumar, Mohit Kumar, Anurag Kumar Gautam, Archana Bharti Sonkar, Abhishek Verma, Amita Singh, Raquibun Nisha, Umesh Kumar, Dinesh Kumar, Tarun Mahata, Bolay Bhattacharya, Biswanath Maity, Abhishek Pandeya, Sunil Babu Gosipatala, Sudipta Saha
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2022-01-01 |
Deskripsi
Fluvoxamine's (FLX's) anticancer potential was investigated in pre-clinical research utilizing a DMH-induced colorectal cancer (CRC) rat model. qRT-PCR and immunoblotting validated the mechanistic investigation. The CRC condition was induced in response to COX-2 and IL-6, however, following FLX therapy, the condition returned to normal. FLX's anti-CRC potential may be attributable to COX-2 inhibition since this molecular activity was more apparent for COX-2 than IL-6. FLX repaired the altered metabolites linked to CRC rats, according to 1H-NMR analysis. FLX was shown to be similar to 5-FU in terms of tumor protection, which may be useful in future medication development.